[8-K] Avalo Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. (Nasdaq: AVTX) filed a Form 8-K dated June 20 2025 to notify investors that it has posted an updated investor presentation on its corporate website.

• Item 8.01 – Other Events: The new presentation will be used in future investor meetings and is furnished as Exhibit 99.1.
• Item 9.01 – Exhibits: 99.1 (Investor Presentation) and 104 (cover pages in Inline XBRL) were included.

The filing contains no new financial statements, earnings guidance, or transactional announcements. Accordingly, the disclosure is primarily informational and does not indicate any immediate operational or strategic change.

Insights

Financial Analyst

TL;DR: Routine 8-K; only furnishes an investor deck, no financial or strategic updates—neutral for valuation.

The company merely alerted the market to an updated slide deck. Because no revenue figures, pipeline data, or guidance changes are provided in the 8-K itself, the filing does not alter cash-flow forecasts or risk profiles. Investors should review Exhibit 99.1 for details, but the act of posting a deck is a normal IR practice and is not, by itself, material. Overall impact on AVTX share value is neutral.

Corporate Governance Expert

TL;DR: Standard disclosure enhances transparency; does not trigger governance or compliance concerns.

Furnishing the presentation via an 8-K ensures simultaneous public access, aligning with Reg FD best practices. The inclusion of Inline XBRL cover pages meets modern SEC formatting standards. There are no board actions, executive changes, or governance red flags disclosed. Therefore, the item is procedurally sound but not impactful beyond routine compliance.

0001534120false00015341202025-06-202025-06-20

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549  

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 20, 2025

AVALO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)  

Delaware

(State or other jurisdiction of incorporation)

001-37590						45-0705648
(Commission File Number)						(IRS Employer Identification No.)

1500 Liberty Ridge Drive, Suite 321, Wayne, Pennsylvania 19087

(Address of principal executive offices) (Zip Code)

Registrant’s Telephone Number, Including Area Code: (410) 522-8707

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, $0.001 Par Value			AVTX			Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01    Other Events.

On June 20, 2025, Avalo Therapeutics, Inc. posted on its website an updated investor presentation (the “Investor Presentation”). The Investor Presentation will be used from time to time in meetings with investors. A copy of the Investor Presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01    Financial Statements and Exhibits.

(d)    Exhibits:

Exhibit No.						Description
99.1						Investor Presentation.
104						The cover pages of this Current Report on Form 8-K, formatted in Inline XBRL.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

									AVALO THERAPEUTICS, INC.
Date: June 20, 2025						By:			/s/ Christopher Sullivan
									Christopher Sullivan
									Chief Financial Officer

2

FAQ

What did Avalo Therapeutics (AVTX) announce in its June 20 2025 Form 8-K?

The company posted an updated investor presentation on its website and furnished it as Exhibit 99.1.

Does the June 20 2025 8-K contain new financial results for AVTX?

No. The filing includes no financial statements, earnings figures, or guidance updates.

Where can investors access the updated Avalo Therapeutics investor deck?

It is available on the company’s website and attached to the 8-K as Exhibit 99.1.

Are there any material events or transactions disclosed in this 8-K?

No. The report solely discloses the availability of an investor presentation; no material events are reported.

What exhibits accompany the Avalo Therapeutics June 20 2025 8-K filing?

Exhibit 99.1 (Investor Presentation) and Exhibit 104 (cover pages in Inline XBRL).